ANIMA Clinical
Board
4 directors, since incorporationBambridge BV
Director (not named in the articles), permanent representative DE CLIPPEL Erik
appointed by deed of 31-07-2025
term without a fixed end
also on the board of 1 other company
Director (not named in the articles), permanent representative VERMEULEN Sven
appointed by deed of 31-07-2025
term without a fixed end
also on the board of 25 other companies
Director (not named in the articles)
appointed by deed of 31-07-2025
term without a fixed end
Director (not named in the articles), permanent representative BUNTINX Erik
appointed by deed of 31-07-2025
term without a fixed end
also on the board of 3 other companies
- Signing authorityThe articles say who may bind the company, for example by signing a contract.
- “Artikel 21: Vertegenwoordiging De vennootschap wordt in al haar handelingen, met inbegrip van de vertegenwoordiging in rechte, rechtsgeldig…”deed of 31-07-2025
Permanent representatives 3
VERMEULEN Sven
Permanent representative, for BNP Paribas Fortis Private Equity Management
appointed by deed of 31-07-2025
Mandates through the years
4 names, the dashed line is todayBambridge
Director (not named in the articles)
Director (not named in the articles)
BNP Paribas Fortis Private Equity Management
Director (not named in the articles)
Director (not named in the articles)
BUNTINX Maren
Director (not named in the articles)
Director (not named in the articles)
EB Pharma Developments
Director (not named in the articles)
Director (not named in the articles)
Board
Mandates as a list
- Bambridge
- Director (not named in the articles), appointed by deed of 31-07-2025, still in office
- BNP Paribas Fortis Private Equity Management
- Director (not named in the articles), appointed by deed of 31-07-2025, still in office
- BUNTINX Maren
- Director (not named in the articles), appointed by deed of 31-07-2025, still in office
- EB Pharma Developments
- Director (not named in the articles), appointed by deed of 31-07-2025, still in office
Control
Parent
Equity €2.7m
Loss €2.2m in 2025 (profit €531,056 in 2024)
Checked score 54
Source: accounts Anima Research 2025
100%
This company
ANIMA Clinical
Capital
- Contribution
- €30,000
- Shares
- 3,000
- Contribution per share
- €10
- Source
- deed of 31-07-2025
Articles of association
deed of 31-07-2025 (in Dutch)- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimited
- Board ruleThese rules set how the board is made up, meets and takes decisions.
- At least 3 directors“In het geval er een vacature openvalt door het overlijden, terugtreden of ontslag van een bestuurder, hebben de overblijvende bestuurders…”“Het bestuursorgaan benoemt één van de Founder Bestuurders als voorzitter van het bestuursorgaan (de “Voorzitter”). De Voorzitter heeft een…”“Vergaderingen bestuursorgaan, In uitzonderlijke omstandigheden kan de oproepingstermijn korter zijn.”“Iedere bestuurder kan per brief, per e-mail of op een andere schriftelijke wijze aan een ander bestuurder volmacht geven om hem op een…”“Besluiten vereisen positieve stem van Investeerder Bestuurder, gewone meerderheid van stemmen van de aanwezige of vertegenwoordigde…”
- Financial yearThe company draws up its annual accounts over this twelve-month period.
- From 1 January to 31 December
- Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
- First Monday of June at 19:00
Capital transactions
Shareholders according to the deeds
At incorporation
deed of 31-07-2025 ↗
- ANIMA RESEARCH (BE 0452.135.608) 3,000 shares (100%) · €30,000
Capital over time
- 31-07-2025 Incorporation · €30,000 · 3,000 shares